Publications:94
Bart S Ferket, MD, PhD
About Me
Dr. Ferket received his MD from the University of Amsterdam in the Netherlands and an MSc degree in Clinical Epidemiology from the Netherlands Institute for Health Sciences. He holds a PhD in Clinical Epidemiology and Radiology (with a focus on Medical Decision Making) from the Erasmus University Medical Center in Rotterdam.
Language
English
Position
ADJUNCT ASSOCIATE PROFESSOR | Population Health Science and Policy
Education
MD, Academic Medical Center, University of Amsterdam
MSc, Netherlands Institute for Health Sciences
PhD, Erasmus Medical Center, Erasmus University
Awards
2016
Mentored Clinical and Population Research Award
American Heart Association
Research
Dr. Ferket's research focuses on applying quantitative methods to identify the best medical decisions for patient populations and the individual patient. He employs mathematical modeling and computer simulation techniques to estimate health and economic outcomes following healthcare interventions, which can be expected for individual risk profiles based on data from clinical trials, population cohort studies, electronic health records and administrative claims databases. He has performed various decision and prognostic modeling studies to evaluate health benefits, risks and economic outcomes for different chronic, non-communicable disease types with the purpose of a) guiding policy makers in decision making at the population level and b) guiding the individual and his/her physician in selecting the optimal medical option(s). His research particularly concerns: 1) prevention of cardiovascular disease, 2) value of surgical procedures, and 3) utility of novel biomarkers and imaging tests.
Publications
Selected Publications
- Adherence to GLP-1 receptor agonists and SGLT2 inhibitors by out-of-pocket spending among Medicare beneficiaries with diabetes. Nicklas S. Klepser, Ellerie S. Weber, Lihua Li, Kirsten E. Fleischmann, Umesh Masharani, Meyeon Park, Wendy B. Max, Joseph Yeboah, M. G.Myriam Hunink, Bart S. Ferket. Diabetes, Obesity and Metabolism
- Biomarker Panels for Discriminating Risk of CKD Progression in Children. Jason H. Greenberg, Alison G. Abraham, Yunwen Xu, Jeffrey R. Schelling, Steven G. Coca, Sarah J. Schrauben, F. Perry Wilson, Sushrut S. Waikar, Ramachandran S. Vasan, Orlando M. Gutiérrez, Michael G. Shlipak, Joachim H. Ix, Bradley A. Warady, Paul L. Kimmel, Joseph V. Bonventre, Chirag R. Parikh, Michelle Denburg, Susan Furth, Alison Abraham, Amanda Anderson, Shawn Ballard, Joseph Bonventre, Clary Clish, Heather Collins, Steven Coca, Josef Coresh, Rajat Deo, Michelle Denburg, Ruth Dubin, Harold I. Feldman, Bart S. Ferket, Meredith Foster, Susan Furth, Peter Ganz, Daniel Gossett, Morgan Grams, Orlando M. Gutiérrez, Tom Hostetter, Lesley A. Inker, Joachim Ix, Paul L. Kimmel, Jon Klein, Andrew S. Levey, Joseph Massaro, Gearoid McMahon, Theodore Mifflin, Girish N. Nadkarni, Chirag Parikh, Vasan S. Ramachandran, Casey Rebholz. Journal of the American Society of Nephrology
- Defining Kidney Health Dimensions and Their Associations with Adverse Outcomes in Persons with Diabetes and CKD. Vanessa Giselle Peschard, Rebecca Scherzer, Michelle M. Estrella, Mark J. Sarnak, Simon B. Ascher, James Lash, Joseph V. Bonventre, Jason H. Greenberg, Orlando M. Gutierrez, Jeffrey R. Schelling, Ronit Katz, Katharine L. Cheung, Emily B. Levitan, Sarah J. Schrauben, Mary Cushman, Titilayo O. Ilori, Chirag R. Parikh, Paul L. Kimmel, Panduranga S. Rao, Jonathan J. Taliercio, James Sondheimer, Rachel Shulman, Steven G. Coca, Jing Chen, Vasan S. Ramachandran, Joachim H. Ix, Michael G. Shlipak, Joseph Massaro, Clary Clish, Jeffrey Schelling, Tom Hostetter, Michelle Denburg, Susan Furth, Bradley Warady, Joseph Bonventre, Sushrut Waikar, Gearoid McMahon, Venkata Sabbisetti, Josef Coresh, Morgan Grams, Casey Rebholz, Alison Abraham, Adriene Tin, Jon Klein, Steven Coca, Bart S. Ferket, Girish N. Nadkarni, Eugene Rhee, Erwin Bottinger, Ilse Daehn. Clinical Journal of the American Society of Nephrology
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Ferket did not report having any of the following types of financial relationships with industry and other outside entities during 2025 and/or 2026: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.